TSHA

Taysha Gene Therapies Stock Analysis

AI Rating

Fair
  • Quality1/10
  • Growth↓ 0/10
  • Momentum↑ 9/10
Taysha Gene Therapies sales and earnings growth
TSHA Growth
Low
  • Revenue Y/Y↓ -36.36%
  • EPS Y/Y↓ -152.38%
  • FCF Y/Y↓ -7.22%
Taysha Gene Therapies gross and profit margin trends
TSHA Profitability
Low
  • Gross margin ↑ 100.00%
  • EPS margin↓ -1583.70%
  • ROIC↓ -185.10%
Taysha Gene Therapies net debt vs free cash flow
TSHA Risk
Great
  • Debt / Equity↓ 0.3
  • Debt / FCF↓ 0.0
  • Interest coverage↓ -1367.9

Taysha Gene Therapies stock volatility is in-line with the overall market. We give it a Great risk rating.

More Biotechnology stocks ↗